RCT | Mirikizumab outperforms placebo in inducing and maintaining remission in ulcerative colitis

Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Mirikizumab Bests Placebo in Treating Patients With Ulcerative Colitis – HCP Live

Commentary on Twitter

In two placebo-controlled, phase 3 trials, mirikizumab, a p19-directed anti–interleukin-23 antibody, was superior with regard to clinical remission of ulcerative colitis at 12 weeks (induction) and 40 weeks (maintenance). https://t.co/H4reu33hF1

— NEJM (@NEJM) June 28, 2023